Ligelizumab
Based on 1 publication(s) in Google Scholar
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.85%
- CAS. Nr.: 1322627-61-1
- Molecular Weight:146.32 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Ligelizumab
More
Biologische Aktivität
Human IgG1 kappa
Human
IGHE
Ligelizumab is more effective than Omalizumab (HY-P9950) in blocking the binding of free IgE to FcεRI on plasmacytoid dendritic cells (pDCs)[2].
In vitro, Ligelizumab can restore the ability of pDCs to produce IFN-α stimulated by TLR9-L, and the effect is better than Omalizumab[2].
In in vitro co-culture experiments, Ligelizumab can restore the ability of pDCs to induce the generation of regulatory T cells (Tregs) like Omalizumab[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human FcεRIα transgenic (huFcεRIα tg) mice on a mixed C57BL/6J-C57BL/6N background[1]
-
Dosage:10 μg of Ligelizumab
-
Administration:Intraperitoneal injection once, administered on day 0 before sensitization with IgE, and antigen challenge on day 1
-
Result:Completely protected the mice from antigen-induced systemic anaphylaxis, as evidenced by no significant decrease in core body temperature after challenge.
Significantly lowered the levels of IgE on peritoneal mast cells compared to omalizumab-treated mice, which only showed partial protection.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 1322627-61-1
-
Appearance Liquid
-
Molecular Weight 146.32 kDa
-
Color Colorless to light yellow
-
SMILES
[Ligelizumab]
-
Synonyms
QGE 031; Anti-IGHE Recombinant Antibody
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Arch Dermatol Res
From wheal to wellness: efficacy and safety of ligelizumab in chronic spontaneous urticaria: a systematic review and meta-analysis. [Abstract]2025 Feb 27;317(1):503. PMID: 40014098
Reinheit & Dokumentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Gasser P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020 Jan 8;11(1):165. [Content Brief]
[2]. Benito-Villalvilla C, et al. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation. Allergy. 2023 Apr;78(4):1060-1072. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)